Program
TQB3911
A development code. Also written as “TQB3911 tablets”.
In Sino Biopharmaceutical's pipeline, BCR-ABL1酪氨酸激酶抑制剂
. Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, led by Sino Biopharmaceutical.
Furthest: phase 1, since Oct 27, 20241 company-led study, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 11 open or running | phase 1since Oct 27, 2024 | Oct 27, 2024 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
TQB3911
, phase 1, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 27, 2024First study: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveFirst studyNCT06672263 · 120 planned · China
TargetBeta
“BCR-ABL1酪氨酸激酶抑制剂”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| imatinibrule | Novartis | phase 4 | 70 |
| nilotinibrule | Novartis | phase 4 | 57 |
| asciminibrule | Novartis | phase 4 | 16 |
| olverembatinibrule | Ascentage Pharma Group International | phase 3 | 10 |
| Embibatinib | Hansoh Pharmaceutical Group | phase 3 | 7 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06672263Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China | 1 | Not yet recruiting | Sep 2026 | 120 |
How it is read
Names in the registry
- “TQB3911 tablets”, 1 entry
Codes read as this program: TQB3911.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.